FY2024 EPS Estimates for Celldex Therapeutics, Inc. (NASDAQ:CLDX) Boosted by Cantor Fitzgerald

Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) – Stock analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for Celldex Therapeutics in a research report issued on Monday, August 12th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will post earnings per share of ($2.62) for the year, up from their previous […]

Leave a Reply

Your email address will not be published.

Previous post Cantor Fitzgerald Comments on Omeros Co.’s FY2024 Earnings (NASDAQ:OMER)
Next post StockNews.com Downgrades Armstrong World Industries (NYSE:AWI) to Hold